This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Iden…

Relapsed/Refractory B-cell Malignancies

~Estimated

~$10 – $8,750

Accutar Biotechnology IncNCT05780034

Phase 1

A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with rela…

Relapsed/Refractory B-cell Malignancies

~Estimated

~$10 – $8,750

Ubix Therapeutics, Inc.NCT06590961